BERKELEY, Calif. — XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, today announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta , in Type 1 diabetes patients.
XOMA 052 Phase 2 Trial Initiated In Type 1 Diabetes Patients
Related posts:
- Phase 2 Trial Of XOMA 052 To Be Initiated In Type 1 Diabetes Patients BERKELEY, Calif. — XOMA Ltd. , a leader in the...
- XOMA Initiates Phase 2b Dose Ranging Clinical Trial Of XOMA 052 In Type 2 Diabetes Patients BERKELEY, Calif. — XOMA Ltd. , a leader in the...
- XOMA Announces Initiation Of Its Phase 2 Clinical Program For XOMA 052 In Type 2 Diabetes And Cardiovascular Disease BERKELEY, Calif. — XOMA Ltd. today announced plans for the...
- XOMA Announces Positive Results From U S Phase 1 Trial Of XOMA XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development...
- Enrollment Completed In Phase 1 Program For XOMA 052 In Type 2 Diabetes BERKELEY, Calif., April 30, 2009 — XOMA Ltd. , a...
